The new antipsychotic compounds: Is a clinical choice algorithm possible?

Western Journal of Medicine

Volumn 169, Issue 1, 1998, Pages 43-44

  Wirshing, William C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ALGORITHM; BLOOD DYSCRASIA; CARDIOTOXICITY; CLINICAL TRIAL; DRUG CHOICE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LIVER TOXICITY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; SCHIZOPHRENIA; SEDATION; SEIZURE; SHORT SURVEY; TACHYCARDIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0031874453     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (1)

1. Brecher M, Titusville N, Janssen Research Foundation, Clyde C, the Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Presented at the 8th Congress of the International Psychogeriatric Association (IPA); 1997 Aug 17-22; Jerusalem, Israel